Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — Q2 2025 Earnings Presentation
22 slides from Burjeel's earnings presentation, August 2025
Slide 1: Q2 & H1 2025 Results
August 2025 Q2 & H1 2025 Results Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in MENA
Slide 4: Q2'25: Delivering Growth — Embedding Efficiency
Q2’25: Delivering Growth — Embedding Efficiency Financial Highlights Strategic Action Execution Highlights Impact Revenue • Record outpatient Utilize Capacity growth in April–May 2025 • Sustained double-digit Post-Ramadan patient footfall growth • Reversed March softness Q1’25 AED1,274m 1,403m Q2’25
Slide 5: Recent Business Developments
Recent Business Developments Launched Regional Mental Health Platform Opened four AlKalma centers across UAE and KSA, addressing growing demand for multidisciplinary mental health services through integrated treatment models and long-term expansion plans. Strengthened Oncology Leadership Expanded Bu
Slide 6: Advancing Specialized Care Through Innovation
Advancing Specialized Care Through Innovation Transforming Limb Restoration Recent Breakthroughs in Complex Care The Middle East’s First Osseointegration Clinic Revolutionary solution Global access at lower cost: for amputees: direct Comparable to US ($95k–$150k) bone-anchored prosthetics at signifi
Slide 7: Milestones Over the Last 12 Months Driving Unmatched Growth & Complex Care Leadership
Milestones Over the Last 12 Months Driving Unmatched Growth & Complex Care Leadership Expanding Advancing Complex Care Embedding Medical Building Global Healthcare Network Capabilities Excellence & Innovation Partnerships Advanced Oncology & UAE’s Largest UAE’s 1st Operating multi- Day Surgery Cente
Slide 8: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in MENA
Slide 9: Patient Growth Accelerates with Expanding Market Presence
Patient Growth Accelerates with Expanding Market Presence Group Inpatient Footfall, k Group Outpatient Footfall, k % bed occupancy % OP utilisation 65% 69% 64% 69% • The Group delivered strong inpatient footfall 69% 68% 69% 65% • Outpatient footfall growth accelerated to growth in Q2’25, supported b
Slide 10: Strong Growth Momentum Across Segments Along with Investments in Future Patient Growth
Strong Growth Momentum Across Segments Along with Investments in Future Patient Growth Group Revenue, AED m Group EBITDA, AED m YoY YoY • Top-line growth accelerated in Q2’25, EBITDA margin • Group EBITDA grew YoY in Q2’25, driven by 1,403 +18.7% +59.4% fueled by strong patient footfall growth stron
Slide 11: Burjeel Medical City: Scaling Patient Base & Driving Efficiency Gains
Burjeel Medical City: Scaling Patient Base & Driving Efficiency Gains Total patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy % EBITDA margin 59% 68% 57% 67% 16.6% 17.6% 16.2% 17.3% +13.0% +22.6% 648 +20.8% 301 574 112 246 93 +30.4% +14.7% +21.3% 333 161 291 59 123 48 Q2'24 Q2'25 H1'24 H1'2
Slide 12: Trust Fertility Center: Powering UAE's Fertility Strategy with Rapid Ramp-Up
Trust Fertility Center: Powering UAE’s Fertility Strategy with Rapid Ramp-Up Integral in Burjeel’s Women’s Health Platform H1 AED 27m Total 1,800+ Unique Patient 1,100+ IVF, FET, & IUI ~50% Clinical Pregnancy Rate 2025 Revenue Volumes Cycles Initiated (above global average) Operational Since Dec 202
Slide 13: Top-Line Growth Underpinned by Cost Discipline & Strategic Asset Control
Top-Line Growth Underpinned by Cost Discipline & Strategic Asset Control Group OPEX Breakdown, % of Revenue Group EBITDA Analysis, AED m % EBITDA margin 84.2% 86.2% 83.4% 84.7% 16.2% 21.8% 82.0% 13.0% 12.3% 10.4% 11.1% 11.3% +221 (87) 2.0% 3.0% 3.9% 3.5% 1.9% (65) 25.0% 24.6% 25.7% 25.0% 25.2% +69 3
Slide 14: Strong Cash Flow Conversion & Profit Expansion
Strong Cash Flow Conversion & Profit Expansion Cash Flow from Operating Activities, AED m Group Net Profit Analysis, AED m % FCF conversion2 % Net profit margin 64% 42% 51% 51% 49% 54% 5.5% 10.5% +221 (176) 566 500 358 148 328 +69 212 229 (15) (7) (9) 65 2021 2022 2023 2024 H1'24 H1'25 Q2’24 Revenue
Slide 15: Well-Capitalized Balance Sheet Supporting Growth & Value Creation
Well-Capitalized Balance Sheet Supporting Growth & Value Creation AED m FY 2023 FY 2024 Q2’25 Debt Maturity as of 30 June 2025 Bank balances and cash 170 238 155 287 280 Interest-bearing loans and borrowings 1,164 1,208 1,621 245 258 237 225 Bank overdrafts – -- -- Bank debt1 1,164 1,208 1,621 Net d
Slide 16: Operonix: Scaling Asset-Light Growth Through Strategic O&M Partnerships
Operonix: Scaling Asset-Light Growth Through Strategic O&M Partnerships Approach Scope of Services 12% Contribution to H1’25 Partnering with Hospital O&M ER/Critical Care O&M 365k+ Net Profit Ministries of Health, Comprehensive hospital 24/7 Emergency and ICU Annual Patient Defense, and Sovereign ad
Slide 17: DOCKTOUR: Expanding Healthcare Access Across Africa Through Strategic Partnership with AD Ports
DOCKTOUR: Expanding Healthcare Access Across Africa Through Strategic Partnership with AD Ports Mission to scale healthcare access Container Field Hospital in under-served regions in Africa Mobility Fast Deployment Easy to transport by land or sea, Delivered and installed 50% 50% and rapidly assembl
Slide 18: Guidance
Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 19: Maintaining Growth Momentum While Building Future Margin Strength
Maintaining Growth Momentum While Building Future Margin Strength FY 2025 (Updated) Mid-term (2027-2028) • UAE: 1 advanced care oncology center (Dubai), • UAE: 1 hospital (Dubai), 1 day surgery center (RAK), Expansion 1 fertility clinic (Al Ain), 6 medical centers 3 medical centers • KSA: 1 day surg
Slide 20: Q&A Appendix
Q&A Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 21: Group & Segment Financial Summary
Group & Segment Financial Summary Group Financial Summary Segmental Financial Summary AED millions Q2’25 Q2’24 H1’25 H1‘24 AED millions Q2’25 Q2’24 H1’25 H1‘24 Revenue 1,403 1,182 2,677 2,387 Revenue 1,403 1,182 2,677 2,387 Inventories consumed (360) (295) (674) (597) Hospitals2 1,245 1,062 2,371 2,
Slide 22: IR Contacts
IR Contacts August 2025 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website